Results 111 to 120 of about 152,178 (350)

ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer [PDF]

, 2012
PMCID: PMC3446380This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided ...
A Borg, AC Wolff, Adrian Harris, C Wright, DA Budwit-Novotny, DJ Slamon, DJ Slamon, E Tagliabue, EA Musgrove, EHR Perez, G Arpino, G Konecny, GD Lewis Phillips, Georges Sumo, IL Andrulis, Isabel Pinhel, Ivana Sestak, J Cuzick, J Vandesompele, JA Sparano, Jack Cuzick, Janine Salter, JC Brase, JM Harvey, Judith M Bliss, M Dowsett, M Dowsett, M Harigopal, Margaret Hills, ME Hammond, MF Press, Mitch Dowsett, MJ Ellis, MJ Ellis, MJ Piccart-Gebhart, N Quenel, P Royston, Peter Barrett-Lee, RL Camp, Roger A'Hern, S Drury, S Johnston, S Paik, SJ Houston, SS Badve, Suzanne Drury, The Adjuvant Breast Cancer Trials Collaborative Group, V Guarneri, VS Perez   +48 more
core   +5 more sources

Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial.

JAMA Oncology, 2020
Importance Prospective assessment of treatments known to benefit patients in global clinical trials in specific racial groups is essential. Objective To compare the efficacy, safety, and tolerability of adding pertuzumab to trastuzumab and docetaxel vs
Z. Shao, D. Pang, Hongjian Yang, Wei Li, Shusen Wang, S. Cui, N. Liao, Yongsheng Wang, Chuanwang Wang, Yuan-Ching Chang, Hwei‐Ming Wang, S. Kang, J. Seo, K. Shen, Suphawat Laohawiriyakamol, Zefei Jiang, Junjie Li, Julian Zhou, B. Althaus, Y. Mao, J. Eng-Wong   +20 more
semanticscholar   +1 more source

Dynamic Binder Exchange Improves Protein Labeling Efficiency in DNA‐PAINT up to 15‐Fold

Angewandte Chemie International Edition, EarlyView.
Dynamic Binder Exchange (DyBE) leverages transient binder–target interactions to enhance labeling efficiency by up to 15‐fold in super‐resolution microscopy. DyBE maps nanoscale receptor tyrosine kinase (RTK) assemblies, including HER2 homodimers and EGFR–HER2 heterodimers, advancing single‐protein spatial proteomics.
Clemens Steinek, Isabelle Pachmayr, Sebastian Strauss, Monique Honsa, Jisoo Kwon, Ralf Jungmann   +5 more
wiley   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

The effect of trastuzumab on taxane-induced peripheral neuropathy in women with breast cancer: a population-based cohort study [PDF]

, 2022
Ruchit Patel, Josee Lyne-Ethier, Susan B. Brogly, Rebecca Griffiths, J. Michael Hendry   +4 more
openalex   +1 more source

Main factors associated with variability in the assessment of the objective response rate. A re‐analysis of the PHEREXA phase 3 clinical trial

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Local investigators (LIs) overestimate the objective response rate (ORR) in comparison to Blinded Independent Central Reviewers (BICR) in oncology. In this study, we re‐analysed data obtained in the PHEREXA trial (NCT01026142) with the following aims: i) to confirm at the single‐patient level the discrepancy observed by analysing ...
Gennaro Daniele, Tommaso Giovagnoli, Pierluigi Navarra, Cinzia Dello Russo   +3 more
wiley   +1 more source

Exosome-mediated lncRNA AFAP1-AS1 promotes trastuzumab resistance through binding with AUF1 and activating ERBB2 translation

Molecular Cancer, 2020
Although trastuzumab provides significant clinical benefit for HER2-positive breast cancers, responses are limited by the emergence of resistance. Recent evidence suggests that long noncoding RNAs (lncRNAs) play important roles in tumorigenesis and ...
Mingli Han, Yuanting Gu, Pengwei Lu, Jingyi Li, H. Cao, Xiang-ke Li, Xueke Qian, Chao Yu, Yunqing Yang, Xue Yang, N. Han, Dong-wei Dou, Jianguo Hu, Huaying Dong   +13 more
semanticscholar   +1 more source

Proceedings of the biosimilars workshop at the International Symposium on Oncology Pharmacy Practice 2019. [PDF]

, 2020
The International Society of Oncology Pharmacy Practitioners organized a workshop to create learning opportunities on biosimilars in pharmacy practice on 10 October 2019.
Chan, Alexandre, Ke, Yu, Tan, Chia Jie
core  

Marine silicon for biomedical sustainability

BMEMat, EarlyView.
Schematic illustrating marine silicon for biomedical engineering. Abstract Despite momentous divergence from oceanic origin, human beings and marine organisms exhibit elemental homology through silicon utilization. Notably, silicon serves as a critical constituent in multiple biomedical processes.
Yahui Han, Zhibo Yang, Wei Xia, Chengtie Wu   +3 more
wiley   +1 more source

Trastuzumab-Deruxtecan: Neue Ära bei HER2-low mBC [PDF]

, 2023

openalex   +1 more source